Latest Articles
Merck's endometrial cancer drug meets late-stage trial goals - AOL.com
Merck's endometrial cancer drug meets late-stage trial goals AOL.com
Published: May 24, 2026, 8:39 p.m.
Mali Barbi: Groundbreaking ASCO26 Results Revealing Potential Cure in Advanced Endometrial Cancer - Oncodaily
Mali Barbi: Groundbreaking ASCO26 Results Revealing Potential Cure in Advanced Endometrial Cancer Oncodaily
Published: May 24, 2026, 1:05 p.m.
Endometrial cancer: Why the patient’s voice needs to be part of the treatment plan - MSN
Endometrial cancer: Why the patient’s voice needs to be part of the treatment plan MSN
Published: May 23, 2026, 11:20 p.m.
Merck Announces Positive Phase 3 Results for Endometrial Cancer Drug - HarianBasis.co
Merck Announces Positive Phase 3 Results for Endometrial Cancer Drug HarianBasis.co
Published: May 23, 2026, 1:10 p.m.
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - MSN
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial MSN
Published: May 23, 2026, 12:41 p.m.
Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints - Yahoo Finance
Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints Yahoo Finance
Published: May 23, 2026, 12:01 p.m.
Merck's ADC candidate meets goals in endometrial cancer study - MSN
Merck's ADC candidate meets goals in endometrial cancer study MSN
Published: May 23, 2026, 3:57 a.m.
Advances in Molecular Profiling and GLP-1 Therapy Offer Hope in Endometrial Cancer - Pharmacy Times
Advances in Molecular Profiling and GLP-1 Therapy Offer Hope in Endometrial Cancer Pharmacy Times
Published: May 22, 2026, 4:14 p.m.
Can GLP-1 Receptor Agonists Improve Outcomes in Patients at Risk for Endometrial Cancer? - Pharmacy Times
Can GLP-1 Receptor Agonists Improve Outcomes in Patients at Risk for Endometrial Cancer? Pharmacy Times
Published: May 22, 2026, 4:29 a.m.
Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer, Full Data Due at ASCO 2026 - OncLive
Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer, Full Data Due at ASCO 2026 OncLive
Published: May 22, 2026, 3:43 a.m.
Link copied to clipboard!